Reversal of Apixaban in Life-Threatening Bleeding

First-Line Reversal Strategy

For life-threatening bleeding in patients taking apixaban, andexanet alfa is the recommended specific reversal agent, as stated by the American College of Cardiology 1, 2, 3
The dosing regimen of andexanet alfa depends on the last dose of apixaban and timing of the last dose, with a low dose being 400 mg IV bolus over 15 minutes followed by a continuous infusion of 480 mg over 2 hours, and a high dose being 800 mg IV bolus over 30 minutes followed by a continuous infusion of 960 mg over 2 hours 1, 2

Reversal should be considered in scenarios of life-threatening bleeding, such as intracranial hemorrhage, expanding or uncontrollable hemorrhage, as recommended by the Journal of Thrombosis and Haemostasis 4, 5
Bleeding in a critical organ or closed space, such as intraspinal, intraocular, pericardial, pulmonary, or retroperitoneal, also warrants reversal, according to the Journal of Thrombosis and Haemostasis 4, 5

Early assessment of laboratory coagulation tests and direct measurements of DOAC levels is recommended, with anti-Xa activity assays being preferred for quantifying apixaban levels, as stated by the World Journal of Emergency Surgery and the Journal of Thrombosis and Haemostasis 1, 5, 6
A threshold of >50 ng/mL is generally considered clinically significant for patients with serious bleeding, according to the World Journal of Emergency Surgery 6

If andexanet alfa is not available, four-factor prothrombin complex concentrates (4F-PCCs) may be administered at a recommended dose of 2000 units, as suggested by the World Journal of Emergency Surgery 1, 7

Monitoring for thromboembolic events is necessary, as they occur in approximately 10% of patients receiving andexanet alfa, according to the Journal of Thrombosis and Haemostasis 8
The duration of andexanet alfa reversal effect is approximately 2 hours after the infusion is stopped, as reported by the Journal of Thrombosis and Haemostasis 4

Andexanet alfa was approved under accelerated approval based on change in anti-FXa activity in healthy volunteers, and the ANNEXA-4 study showed that it reduced anti-FXa activity by approximately 93% and achieved good or excellent hemostasis in 80% of patients, as stated by the Journal of Thrombosis and Haemostasis 8